Travere Therapeutics, Inc. TVTX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $93.04M+58.9% | $58.54M+0.6% | $58.18M-5.7% | $61.69M-62.8% | ||
| $145.38M— | —— | $248.64M-12.9% | $285.53M+8.9% | ||
| $80.13M+196% | $27.12M+28.0% | $21.18M+27.2% | $16.65M+4.6% | ||
| $30.28M-15.1% | $35.66M+13.2% | $31.49M— | $0-100% | ||
| $28.76M+127% | $12.69M-34.4% | $19.34M+60.7% | $12.03M+79.1% | ||
| $437.57M+5.0% | $416.7M-32.4% | $616.78M+26.8% | $486.44M-16.5% | ||
| $4.02M-24.6% | $5.34M-28.7% | $7.48M-17.3% | $9.05M-18.5% | ||
| $10.58M-26.0% | $14.3M-20.9% | $18.06M-14.0% | $21M-9.5% | ||
| $113.87M+9.5% | $103.97M-0.4% | $104.44M+7.6% | $97.07M-34.6% | ||
| $8.88M-51.1% | $18.16M+70.4% | $10.66M-0.2% | $10.68M-3.5% | ||
| $605.19M+1.9% | $594.13M-24.7% | $788.91M+17.3% | $672.59M-13.4% | ||
| $24.8M+5.4% | $23.53M-43.5% | $41.68M+141% | $17.29M+14.2% | ||
| $3.19M-81.3% | $17.11M+227% | $5.24M-8.5% | $5.72M-7.5% | ||
| $5.88M+8.7% | $5.41M+10.1% | $4.91M+10.7% | $4.43M+13.4% | ||
| $159.9M-20.3% | $200.75M+12.8% | $177.91M+25.1% | $142.16M+14.6% | ||
| $11.13M-35.2% | $17.19M-24.0% | $22.61M-17.8% | $27.51M-12.7% | ||
| $17.01M-24.7% | $22.6M-17.9% | $27.52M-13.8% | $31.94M-9.8% | ||
| $7.6M+11.8% | $6.8M-34.1% | $10.32M+10.0% | $9.39M-23.6% | ||
| $490.36M-8.4% | $535.05M-9.0% | $588.1M-6.6% | $629.73M+839% | ||
| $0— | $0— | $0— | $0— | ||
| $9K0.0% | $9K+28.6% | $7K+16.7% | $6K0.0% | ||
| $1.59B+5.5% | $1.51B+13.4% | $1.33B+25.3% | $1.06B-0.8% | ||
| -$1.47B-1.8% | -$1.45B-28.6% | -$1.13B-11.0% | -$1.01B-32.4% | ||
| -$1.19M-1,386% | -$80K+94.5% | -$1.46M+49.9% | -$2.91M-417% | ||
| $114.83M+94.4% | $59.08M-70.6% | $200.81M+369% | $42.85M-85.8% | ||
| $605.19M+1.9% | $594.13M-24.7% | $788.91M+17.3% | $672.59M-13.4% | ||
| $229.76M-26.4% | $312.17M-38.6% | $508.68M+30.9% | $388.56M+0.4% | ||
| $145.38M— | —— | $248.64M-12.9% | $285.53M+8.9% | ||
| $8.88M-51.1% | $18.16M+70.4% | $10.66M-0.2% | $10.68M-3.5% | ||
| $10.58M-26.0% | $14.3M-20.9% | $18.06M-14.0% | $21M-9.5% | ||
| $113.87M+9.5% | $103.97M-0.4% | $104.44M+7.6% | $97.07M-34.6% | ||
| $10.58M-26.0% | $14.3M-20.9% | $18.06M-14.0% | $21M-9.5% | ||
| $8.88M-51.1% | $18.16M+70.4% | $10.66M-0.2% | $10.68M-3.5% | ||
| $10.58M-26.0% | $14.3M-20.9% | $18.06M-14.0% | $21M-9.5% | ||
| $8.88M-51.1% | $18.16M+70.4% | $10.66M-0.2% | $10.68M-3.5% | ||
| $126.04M+46.5% | $86.03M-27.7% | $118.99M+24.3% | $95.74M+27.4% | ||
| $311.72M— | —— | —— | —— | ||
| $126.04M+46.5% | $86.03M-27.7% | $118.99M+24.3% | $95.74M+27.4% | ||
| $3.19M-81.3% | $17.11M+227% | $5.24M-8.5% | $5.72M-7.5% | ||
| $17.01M-81.4% | $91.27M+232% | $27.52M-13.8% | $31.94M-9.8% | ||
| $9K0.0% | $9K+28.6% | $7K+16.7% | $6K0.0% | ||
| $0— | $0— | $0— | $0— | ||
| $229.76M-26.4% | $312.17M-38.6% | $508.68M+30.9% | $388.56M+0.4% | ||
| $311.72M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Travere Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 3.13 — current assets exceed current liabilities.
- Where does Travere Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.